Halozyme Therapeutics, Inc. · NASDAQ:HALO
Torley Helen sold 1,923 Halozyme Therapeutics, Inc. shares (Form 4)
Traded Jul 8, 2026 · Filed Jul 9, 2026
On Jul 8, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 1,923 Halozyme Therapeutics, Inc. shares at an average US$79.77 for US$153K under a trading plan, leaving 767,780 shares. Filed Jul 9, 2026 (Form 4).
- Sold
- 1,923 shares
- Price
- US$79.77 average (US$79.28 to US$80.19)
- Value
- US$153K
- Holding after
- 767,780 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, PRESIDENT AND CEO
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Common Stock | Option exercise | 1,923 | US$12.07 | 769,703 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 888 | US$79.28 | 768,815 | Direct |
| Jul 8, 2026 | Common Stock | Sale | 1,035 | US$80.19 | 767,780 | Direct |
Source
Related
- Halozyme Therapeutics, Inc.
- Torley Helen
- Halozyme Therapeutics, Inc. shareholders
- Form 4 · Torley Helen · Oct 8, 2026
- Form 4 · Torley Helen · Sep 11, 2026
- Form 4 · Torley Helen · Aug 19, 2026
- Form 4 · Torley Helen · Jun 3, 2026
- Form 4 · Torley Helen · May 13, 2026
- Form 4 · Posard Matthew L. · Oct 2, 2026
- Form 4 · Daly James M · Oct 2, 2026
- Form 4 · Posard Matthew L. · Sep 17, 2026
- Form 4 · Appelhans Dannielle · Sep 2, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026